Systematic Review and Subgroup Analysis of the Incidence of Acute Kidney Injury (AKI) in Patients with COVID-19

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2021 Feb 6

PMID 33546616

Citations 27

Authors

Zhenjian Xu

Ying Tang

Qiuyan Huang

Sha Fu

Xiaomei Li

Baojuan Lin

Anping Xu

Junzhe Chen

Affiliations

Soon will be listed here.

Abstract

Background: Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19 patients. The incidence of AKI in different subgroups was also investigated.

Methods: A thorough search was performed to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. The systematic review was performed using the meta package in R (4.0.1).

Results: A total of 16,199 COVID-19 patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 10.0% (95% CI: 7.0-12.0%). The pooled estimated proportion of COVID-19 patients who needed continuous renal replacement therapy (CRRT) was 4% (95% CI: 3-6%). According to our subgroup analysis, the incidence of AKI could be associated with age, disease severity and ethnicity. The incidence of AKI in hospitalized COVID-19 patients being treated with remdesivir was 7% (95% CI: 3-13%) in a total of 5 studies.

Conclusion: We found that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably did not induce AKI in COVID-19 patients. Our systematic review provides evidence that AKI might be closely associated with SARS-CoV-2 infection, which should be investigated in future studies.

Citing Articles

Acute kidney injury in coronavirus disease: a comparative study of the two waves in Brazil.

Magalhaes L, Favarin A, Cardoso P, Yuasa B, Zamoner W, Balbi A Einstein (Sao Paulo). 2024; 22:eAO0687.

PMID: 39356942 PMC: 11461013. DOI: 10.31744/einstein_journal/2024AO0687.

Clinical and Biochemical Characteristics of COVID-19-Associated Acute Kidney Injury (COVAKI): A Proof-of-Concept Case-Control Study.

Kumthekar G, Nagarkar M, Purandare V, Shukla S, Yeravdekar R Cureus. 2024; 16(4):e57763.

PMID: 38715992 PMC: 11074819. DOI: 10.7759/cureus.57763.

A study of hospitalized COVID-19 patients with AKI in a setting of multiracial developing country.

Ooi S, Ng K, Sthaneshwar P, Lim S, Khor P, Lim J BMC Nephrol. 2024; 25(1):122.

PMID: 38580977 PMC: 10998399. DOI: 10.1186/s12882-024-03498-x.

Kidney damage associated with COVID-19: from the acute to the chronic phase.

Nlandu Y, Tannor E, Bafemika T, Makulo J Ren Fail. 2024; 46(1):2316885.

PMID: 38561236 PMC: 10986440. DOI: 10.1080/0886022X.2024.2316885.

The Prediction Score of Acute Kidney Injury in Patients with Severe COVID-19 Infection.

Anumas S, Chueachinda S, Tantiyavarong P, Pattharanitima P J Clin Med. 2023; 12(13).

PMID: 37445447 PMC: 10342471. DOI: 10.3390/jcm12134412.

References

Ferguson J, Rosser J, Quintero O, Scott J, Subramanian A, Gumma M . Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020; 26(8):1679-1685. PMC: 7392471. DOI: 10.3201/eid2608.201776. View

Price-Haywood E, Burton J, Fort D, Seoane L . Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med. 2020; 382(26):2534-2543. PMC: 7269015. DOI: 10.1056/NEJMsa2011686. View

Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S . Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020; 24(1):188. PMC: 7192564. DOI: 10.1186/s13054-020-02895-6. View

Maan R, Al Marzooqi S, Klair J, Karkada J, Cerocchi O, Kowgier M . The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Aliment Pharmacol Ther. 2017; 46(1):46-55. DOI: 10.1111/apt.14117. View

Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

Su H, Yang M, Wan C, Yi L, Tang F, Zhu H . Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98(1):219-227. PMC: 7194105. DOI: 10.1016/j.kint.2020.04.003. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Lim S, DeBruin D, Leider J, Sederstrom N, Lynfield R, Baker J . Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. Mayo Clin Proc. 2020; 95(9):1946-1954. PMC: 7305893. DOI: 10.1016/j.mayocp.2020.06.016. View

Xing W, Gu L, Zhang X, Xu J, Lu H . A metabolic profiling analysis of the nephrotoxicity of acyclovir in rats using ultra performance liquid chromatography/mass spectrometry. Environ Toxicol Pharmacol. 2016; 46:234-240. DOI: 10.1016/j.etap.2016.07.018. View

10.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A . Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24):2327-2336. PMC: 7169476. DOI: 10.1056/NEJMoa2007016. View

11.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View

12.

Chu K, Tsang W, Tang C, Lam M, Lai F, To K . Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005; 67(2):698-705. PMC: 7112337. DOI: 10.1111/j.1523-1755.2005.67130.x. View

13.

Williamson B, Feldmann F, Schwarz B, Meade-White K, Porter D, Schulz J . Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020; 585(7824):273-276. PMC: 7486271. DOI: 10.1038/s41586-020-2423-5. View

14.

Forest S, Michler R, Skendelas J, DeRose J, Friedmann P, Parides M . De Novo Renal Failure and Clinical Outcomes of Patients With Critical Coronavirus Disease 2019. Crit Care Med. 2020; 49(2):e161-e169. DOI: 10.1097/CCM.0000000000004785. View

15.

Wang L, Li X, Chen H, Yan S, Li D, Li Y . Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol. 2020; 51(5):343-348. PMC: 7179524. DOI: 10.1159/000507471. View

16.

Chen G, Zhou Y, Ma J, Xia P, Qin Y, Li X . Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?. Ren Fail. 2020; 42(1):483-488. PMC: 7946020. DOI: 10.1080/0886022X.2020.1764369. View

17.

Farkash E, Wilson A, Jentzen J . Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. J Am Soc Nephrol. 2020; 31(8):1683-1687. PMC: 7460898. DOI: 10.1681/ASN.2020040432. View

18.

Cai C, Qiu G, Hong W, Shen Y, Gong X . Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury. BMC Nephrol. 2020; 21(1):286. PMC: 7368639. DOI: 10.1186/s12882-020-01945-z. View

19.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

20.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View